ArticlePsychiatry and clinical psychopharmacology2024
Effects of Acceptance and Commitment Care in the Treatment of Aplastic Anemia Patients with Recombinant Human Thrombopoietin.
Article in Psychiatry and clinical psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study was designed to determine the effects of acceptance and commitment care in the treatment of aplastic anemia (AA) patients with recombinant human thrombopoietin (rhTPO). Methods: The clinical records of 100 AA patients treated at our hospital from March 2021 to March 2023 were analyzed in the retrospective study. All patients received immunosuppressants and rhTPO. Among them, 46 patients who received routine care from March 2021 to March 2022 were allocated to the control group, and the other 54 patients who received acceptance and commitment care from April 2022 to March 2023 were assigned to the study group. The quality of life (QoL) of the 2 groups was assessed by the MOS 36-Item Short-Form Health Survey (SF-36) before care and after 3 months of care. Blood-related indicators after care were compared in 2 groups. Results: Before care, no significant inter-group discrepancy was observed in SF-36 scores in all dimensions (P > .05); whereas after nursing, the SF-36 scores of both groups increased conspicuously in all dimensions (P < .001), especially the study group (P < .001). After care, no significant differences were observed in hemoglobin (Hb), platelet count (PLT), and white blood cell count (WBC) between the 2 groups (P > .05). A conspicuously lower overall response rate was observed in the control group in contrast to the study group (P = .044), and no significant inter-group discrepancy was found in the total incidence of adverse reactions (P = .506). Conclusion: Acceptance and commitment care is conducive to the patients with AA treated by rhTPO, because it substantially improves the QoL of patients, without increasing adverse reactions, so it is worth promoting.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.